Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly reminders boost home monitoring in severe asthma patients

NCT ID NCT07393984

Symptom relief Sponsor: University of Medicine and Pharmacy "Victor Babes" Timisoara Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether weekly reminder messages help adults with severe asthma stick to home-based lung function monitoring using a digital device. Thirty patients used the AioCare spirometry system for 12 weeks. Those who got reminders completed more monitoring sessions than those who didn't. No device-related problems were reported.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AioCare home spirometry system (device)
What this could lead to
If successful, this approach could improve how patients with severe asthma manage their condition at home, potentially leading to better symptom control.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply to everyone. The study is completed, but larger trials are needed to confirm benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Oct 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of severe asthma according to GINA guidelines. * Age ≥ 18 years. * Ability to correctly perform spirometry maneuvers according to ATS/ERS standards after training. * Access to a smartphone compatible with the AioCare application. * Willingness to participate in weekly home-based spirometry monitoring and telemonitoring for three months. * Stable maintenance asthma therapy for at least four weeks prior to enrollment. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Age \< 18 years. * Diagnosis of other significant respiratory diseases (including chronic obstructive pulmonary disease, interstitial lung disease, or bronchiectasis). * Asthma exacerbation requiring hospitalization or systemic corticosteroids within the four weeks prior to enrollment. * Severe psychiatric or cognitive impairment that could interfere with adherence to the monitoring protocol or ability to use the device independently. * Inability to perform acceptable spirometry maneuvers despite training. * Lack of smartphone or internet access required for AioCare telemonitoring. * Pregnancy or breastfeeding. * Refusal or inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma chronic asthma Patient Participation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Severe asthma

Contacts and locations

Locations

  • Dr. Victor Babeș Clinical Hospital for Infectious Diseases and Pulmonology, Timișoara

    Timișoara, Timiș County, 300310, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.